SAMA Schultze Special Purpose Acquisition

Clever Leaves Partners with Anden Naturals to Bring Pharmaceutical-Grade Cannabis to Patients in Peru

Clever Leaves Partners with Anden Naturals to Bring Pharmaceutical-Grade Cannabis to Patients in Peru

Peruvian operator Anden Naturals has obtained sanitary registration from the Peruvian Health Authority for its THC dominant products

Clever Leaves will cultivate, manufacture, and pack Anden Naturals’ finished products in its EUGMP certified facilities in Colombia

TOCANCIPÁ, Colombia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today that its partner, Peruvian medicinal cannabis company Anden Naturals, has obtained the sanitary registration for the finished product, “Andenol 50,” a 5% THC dominant oral solution produced by Clever Leaves in Colombia and sold under the Anden Naturals brand in Peru.

Andenol 50, is Anden Naturals’ first THC dominant product to obtain sanitary registration for its commercialization as a finished product and is considered to be a “phytotherapeutic” product, by the Peruvian health authority and indicating passage of all quality inspections. Anden Naturals manufactures and markets medicinal cannabis products in Peru through magistral formulations as well as finished products imported from other countries. The company distributes medical cannabis products through its own pharmacies in the country.

Obtaining this sanitary registration of a THC dominant finished product reflects both the unmatched quality of the medical cannabis cultivated by Clever Leaves and Clever Leaves' rigorous product development processes.

“Our purpose at Clever Leaves is to produce the highest quality medical cannabis products for ourselves, our partners, and most importantly, for the millions of medical cannabis patients worldwide. The fact that Anden Naturals is the very first to obtain this sanitary registration in Peru is further proof that we are living up to our incredibly high standards and those of patients across the globe,” said Andres Fajardo, CEO of Clever Leaves. “Due to the product’s higher THC content, authorities are more demanding in granting the registration and there is greater control over its use, prescription, and commercialization. We are proud to be the leader in setting the standard for every market in which we operate.”

“With the addition of this high THC product, we can now offer a complete portfolio of products to our patients, offering the most robust and diversified portfolio in Peru. We are excited to have partnered up with Clever Leaves to produce Andenol 50, as we wanted to offer the highest possible quality to our patients. They have been a pleasure to work with and we are extremely happy with the attention to detail they have shown throughout the registration process.”

The initial shipment of 1,000 units is set for Q1 of 2023 and the potential market is expected to be 30,000 registered patients, according to data as of August 2022.

About Clever Leaves Holdings Inc.

Clever Leaves is a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids.

Its operations in Colombia and Portugal produce cannabinoid active pharmaceutical ingredients (API) and finished products ​in flower and extract form to a growing base of B2B customers around the globe. Clever Leaves aims to disrupt the traditional cannabis production industry by leveraging environmentally sustainable, ESG-friendly, industrial-scale and low-cost production methods, with the world’s most stringent pharmaceutical quality certifications. For more information, please visit  and follow Clever Leaves on Twitter and LinkedIn.

About Anden Naturals

Anden Naturals is 100% Peruvian owned and operated, a duly licensed producer and importer of high-quality cannabis products, offering the most robust and diversified portfolio of products in Peru. Anden Naturals operates in both the US and Peru. They have launched the first of its kind cannabis dispensary, offering finished products as well as magistral formulations. Anden Naturals has the biggest presence in Peru, having their products in over 45 retail locations. Learn more about Anden Naturals visiting and . 

Press Contacts:

Rich DiGregorio

KCSA Strategic Communications



Clever Leaves Commercial Inquiries:

Andrew Miller

Head of Business Development



Clever Leaves Investor Inquiries:

Cody Slach and Jackie Keshner

Gateway Group, Inc.



 

 



EN
03/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Schultze Special Purpose Acquisition

 PRESS RELEASE

Clever Leaves Announces Voluntary Delisting and SEC Deregistration

Clever Leaves Announces Voluntary Delisting and SEC Deregistration TOCANCIPÁ, Colombia, April 26, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, today announced that its Board of Directors (the “Board”) determined to voluntarily delist its common shares, without par value (the “common shares”) and warrants, each exercisable for 1/30th common share at an exercise price of $11.50 (the “Warrants” and together with the common shares, the “Securities”) from The Nasdaq Stock Market LLC (“Nasdaq”...

 PRESS RELEASE

Clever Leaves Reports Fourth Quarter and Full Year 2023 Results

Clever Leaves Reports Fourth Quarter and Full Year 2023 Results - 2023 Revenue Increased 6% Year-Over-Year, with a 39% Increase in Full-Year Cannabinoid Revenue - - Drove Year-over-Year General and Administrative Expense Reductions of 26% in Q4 2023 and 24% for the Full Year - - Completed Sale of Non-Cannabinoid Herbal Brands Business on March 21, 2024 for $8.02 Million, Including $7.02 Million in Cash Paid at Closing - TOCANCIPÁ, Colombia, April 01, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabi...

 PRESS RELEASE

Clever Leaves and Paradise Seeds to Develop and Register Genetic Asset...

Clever Leaves and Paradise Seeds to Develop and Register Genetic Assets in Colombia TOCANCIPÁ, Colombia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, announced today that through its partnership with award-winning Dutch seed bank, Paradise Seeds (“Paradise”), to develop and register high performance cannabis cultivars in Colombia, Clever Leaves will have exclusive license to cultivate some of these genetics, while Paradise will make other cultivars available to third parties for...

 PRESS RELEASE

Clever Leaves Granted Australian GMP Certification for Cannabis Produc...

Clever Leaves Granted Australian GMP Certification for Cannabis Products by the Therapeutic Goods Administration (TGA) Multinational operator has been granted Australian GMP certification by the TGA for the manufacturing of cannabis products. Clever Leaves is the first and only medicinal cannabis company globally that has GMP certifications from the European Union, Colombia, Brazil and Australia. TOCANCIPÁ, Colombia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW), a global medicinal cannabis company, announced today that it has been granted Australia...

 PRESS RELEASE

Clever Leaves Reports Third Quarter 2023 Results

Clever Leaves Reports Third Quarter 2023 Results - Q3 Revenue Increased 33% Year-Over-Year, Propelled by 135% Year-Over-Year Growth in Cannabinoid Revenue, Along with 6% Year-Over-Year Growth in Non-Cannabinoid Revenue - - Q3 Adjusted EBITDA Improved Year-Over-Year to $(2.6) Million Compared to $(3.7) Million, Reflecting Revenue Growth and Continued Aggressive Expense Reductions - - Cash Balance at October 31, 2023 was $6.2 Million, with $1.9 Million in Subsequent Capital Received from the November Sale of the Company’s Remaining Stake in Cansativa - - Updated Full Ye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch